Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Buy at StockNews.com

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

Several other brokerages also recently commented on ESPR. Needham & Company LLC decreased their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Price Performance

Shares of ESPR opened at $2.21 on Thursday. The firm has a market capitalization of $433.66 million, a P/E ratio of -2.57 and a beta of 0.96. Esperion Therapeutics has a one year low of $0.87 and a one year high of $3.40. The business has a fifty day moving average of $1.90 and a 200 day moving average of $2.13.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. The business had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. Analysts expect that Esperion Therapeutics will post -0.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BOKF NA purchased a new stake in shares of Esperion Therapeutics in the second quarter worth about $26,000. Xponance Inc. purchased a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $28,000. CVI Holdings LLC bought a new position in shares of Esperion Therapeutics during the 1st quarter valued at approximately $37,000. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics in the third quarter valued at $27,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Esperion Therapeutics in the first quarter worth $50,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.